Safikhani, Shima
Gries, Katharine S.
Trudeau, Jeremiah J.
Reasner, David
Rüdell, Katja
Coons, Stephen Joel
Bush, Elizabeth Nicole
Hanlon, Jennifer
Abraham, Lucy
Vernon, Margaret
Funding for this research was provided by:
Patient-Reported Outcome (PRO) Consortium’s Measurement Projects Fund
Article History
Received: 22 November 2017
Accepted: 20 May 2018
First Online: 6 September 2018
Ethics approval and consent to participate
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: SJC reports no employment in a pharmaceutical company nor does he hold stocks, shares, or stock options in a pharmaceutical company. LA is an employee and owns stocks, shares, and stock options for Pfizer Ltd. KG reports she is a current employee at Janssen but reports no stocks, shares, nor options. ENB works for Eli Lilly & Company and holds stocks or shares there, but no stock options. JTH and DSR are salaried employees and own stocks, shares, and stock options at Ironwood Pharmaceuticals. KR is an employee of Shire and owns stock options there. JT is a current employee at Janssen but reports no stocks, shares, nor options. SS and MV are employees of Evidera, a research and consulting firm to the biopharma industry and, as such, are not allowed to accept remuneration from any Evidera clients. None of these authors report any other arrangements that could be perceived as conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.